Polaris III期肺部间皮瘤研究的期中分析显示,研究结束时成功的机率大于80%。
根据2021年2月25日期中分析的数据估计成功的机率,ADI PEG-20比对照组的生存获益,在试验结束时具有 …
根据2021年2月25日期中分析的数据估计成功的机率,ADI PEG-20比对照组的生存获益,在试验结束时具有 …
北极星-KY(6550)在美国进行的肺间皮癌(肺癌的一种)临床试验三期期中分析报告于美国时间2月25日出炉,以现有期中的数据来分析,预估最后整体试验的成功机率在80%以上(80~100%之间)。
台北时间,2020年9月17日 北极星集团今天宣布,在ADI-PEG 20联合放疗和特莫唑胺治疗新诊断多形性神 …
2019年12月13日 Polaris Group 宣布完成 1 亿美元的私募融资。
关于封面 胰腺癌是众所周知的难治之症。针对胰腺癌的一个潜在机会是通过其改变的氨基酸代谢。具体来说,剥夺依赖精氨 …
SAN DIEGO, February 22, 2019 – Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer.
圣地牙哥,2019年2月22日–北极星集团今天宣布,Wayne Lin,MBA,被任命为首席营运长 …
SAN DIEGO, July 8, 2018 — Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board.
SAN DIEGO, July 9, 2018 — Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.
SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI‑PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas. The results were presented by Dr. Peter Szlosarek from Barts Cancer Center in the UK (abstract No.2589) at the American Society Clinical Oncology’s 2018 annual meeting.